NASDAQ:TBIO

Translate Bio Stock Forecast, Price & News

$19.78
+0.55 (+2.86 %)
(As of 04/20/2021 12:00 AM ET)
Add
Compare
Today's Range
$19.07
Now: $19.78
$19.83
50-Day Range
$16.00
MA: $19.29
$25.70
52-Week Range
$9.64
Now: $19.78
$34.64
Volume1.70 million shs
Average Volume1.22 million shs
Market Capitalization$1.49 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.96
Translate Bio, Inc., a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis. It is also developing MRT5500 for the treatment of SARS-CoV-2. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. has a collaboration and license agreement with Sanofi Pasteur Inc. The company was founded in 2011 and is headquartered in Lexington, Massachusetts.
Translate Bio logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TBIO
CUSIPN/A
CIKN/A
Phone617-945-7361
Employees122
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.80 million
Book Value$2.56 per share

Profitability

Net Income$-113,290,000.00

Miscellaneous

Market Cap$1.49 billion
Next Earnings Date5/6/2021 (Estimated)
OptionableNot Optionable

Headlines

Translate Bio (NASDAQ:TBIO) Trading 5% Higher
April 15, 2021 |  americanbankingnews.com
Translate Bio Appoints Dr. Rand Sutherland as President
March 22, 2021 |  finance.yahoo.com
Why Translate Bio Shares Are Tanking Today
March 18, 2021 |  finance.yahoo.com
Zoom Video Leads Five Stocks Racing Past Buy Points
February 6, 2021 |  finance.yahoo.com
See More Headlines

MarketRank

Overall MarketRank

1.56 out of 5 stars

Medical Sector

442nd out of 2,018 stocks

Biological Products, Except Diagnostic Industry

55th out of 177 stocks

Analyst Opinion: 4.3Community Rank: 1.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
$19.78
+0.55 (+2.86 %)
(As of 04/20/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for TBIO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Translate Bio (NASDAQ:TBIO) Frequently Asked Questions

Is Translate Bio a buy right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Translate Bio in the last year. There are currently 4 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Translate Bio stock.
View analyst ratings for Translate Bio
or view top-rated stocks.

What stocks does MarketBeat like better than Translate Bio?

Wall Street analysts have given Translate Bio a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Translate Bio wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Translate Bio's next earnings date?

Translate Bio is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Translate Bio
.

How were Translate Bio's earnings last quarter?

Translate Bio, Inc. (NASDAQ:TBIO) issued its earnings results on Thursday, November, 5th. The company reported $0.23 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.20 by $0.03. The firm had revenue of $66.45 million for the quarter, compared to the consensus estimate of $58.97 million. Translate Bio had a negative trailing twelve-month return on equity of 27.54% and a negative net margin of 70.38%.
View Translate Bio's earnings history
.

How has Translate Bio's stock price been impacted by Coronavirus (COVID-19)?

Translate Bio's stock was trading at $7.43 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, TBIO shares have increased by 166.2% and is now trading at $19.78.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for TBIO?

11 Wall Street analysts have issued 12-month target prices for Translate Bio's shares. Their forecasts range from $18.00 to $40.00. On average, they anticipate Translate Bio's share price to reach $25.70 in the next year. This suggests a possible upside of 29.9% from the stock's current price.
View analysts' price targets for Translate Bio
or view top-rated stocks among Wall Street analysts.

Who are Translate Bio's key executives?

Translate Bio's management team includes the following people:
  • Mr. Ronald C. Renaud Jr., Pres, CEO, Director & Interim Principal Financial Officer (Age 52, Pay $756.15k)
  • Dr. Richard Wooster, Chief Scientific Officer (Age 56, Pay $433.55k)
  • Mr. Paul D. Burgess J.D., Chief Legal Officer, COO & Sec. (Age 47)
  • Mr. Robert D. Prentiss, VP, Corp. Controller, Treasurer & Interim Principal Accounting Officer (Age 49)
  • Mr. Frank DeRosa, Chief Technology Officer
  • Ms. Teri Babine Dahlman, VP of Corp. Communications & Investor Relations
  • Ms. Paula A. Cloghessy, Chief People Officer (Age 50)
  • Mr. Brian Fenton M.S., MBA, Chief Bus. Officer (Age 53)
  • Dr. Ann Barbier M.D., Ph.D., Chief Medical Officer (Age 57)

What is Craig J. Tuttle's approval rating as Translate Bio's CEO?

13 employees have rated Translate Bio CEO Craig J. Tuttle on Glassdoor.com. Craig J. Tuttle has an approval rating of 5% among Translate Bio's employees. This puts Craig J. Tuttle in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Translate Bio's key competitors?

What other stocks do shareholders of Translate Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Translate Bio investors own include Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Novavax (NVAX), Pfizer (PFE), Moderna (MRNA), Johnson & Johnson (JNJ), Sorrento Therapeutics (SRNE), Vaxart (VXRT) and VBI Vaccines (vbiv).

When did Translate Bio IPO?

(TBIO) raised $100 million in an initial public offering on Thursday, June 28th 2018. The company issued 7,700,000 shares at $12.00-$14.00 per share. Citigroup, Leerink Partners and Evercore ISI served as the underwriters for the IPO.

What is Translate Bio's stock symbol?

Translate Bio trades on the NASDAQ under the ticker symbol "TBIO."

Who are Translate Bio's major shareholders?

Translate Bio's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Dfpg Investments LLC (0.04%) and Pacer Advisors Inc. (0.00%). Company insiders that own Translate Bio stock include Baupost Group Llc/Ma, Human Genetic Therapies Shire and Jean Francois Formela.
View institutional ownership trends for Translate Bio
.

Which institutional investors are selling Translate Bio stock?

TBIO stock was sold by a variety of institutional investors in the last quarter, including Pacer Advisors Inc.. Company insiders that have sold Translate Bio company stock in the last year include Human Genetic Therapies Shire, and Jean Francois Formela.
View insider buying and selling activity for Translate Bio
or view top insider-selling stocks.

Which institutional investors are buying Translate Bio stock?

TBIO stock was bought by a variety of institutional investors in the last quarter, including Dfpg Investments LLC.
View insider buying and selling activity for Translate Bio
or or view top insider-buying stocks.

How do I buy shares of Translate Bio?

Shares of TBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Translate Bio's stock price today?

One share of TBIO stock can currently be purchased for approximately $19.78.

How much money does Translate Bio make?

Translate Bio has a market capitalization of $1.49 billion and generates $7.80 million in revenue each year. The company earns $-113,290,000.00 in net income (profit) each year or ($1.84) on an earnings per share basis.

How many employees does Translate Bio have?

Translate Bio employs 122 workers across the globe.

What is Translate Bio's official website?

The official website for Translate Bio is www.translate.bio.

Where are Translate Bio's headquarters?

Translate Bio is headquartered at 29 HARTWELL AVENUE, LEXINGTON MA, 02421.

How can I contact Translate Bio?

Translate Bio's mailing address is 29 HARTWELL AVENUE, LEXINGTON MA, 02421. The company can be reached via phone at 617-945-7361.


This page was last updated on 4/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.